

# Therapeutic Vulnerabilities of Transcription Factors in AML

Irum Khan<sup>1</sup>, Elizabeth E. Eklund<sup>2,3</sup>, and Andrei L. Gartel<sup>1</sup>



## ABSTRACT

Acute myeloid leukemia (AML) is characterized by impaired myeloid lineage differentiation, uncontrolled proliferation, and inhibition of proapoptotic pathways. In spite of a relatively homogeneous clinical disease presentation, risk of long-term survival in AML varies from 20% to 80% depending on molecular disease characteristics. In recognition of the molecular heterogeneity of AML, the European Leukemia Net (ELN) and WHO classification systems now incorporate cytogenetics and increasing numbers of gene mutations into AML prognostication. Several of the genomic AML subsets are characterized by unique transcription factor alterations that are highlighted in this review. There are many mechanisms of transcriptional deregulation in leukemia. We broadly classify transcription factors based on mechanisms of transcriptional deregulation including direct involvement of transcription

factors in recurrent translocations, loss-of-function mutations, and intracellular relocalization. Transcription factors, due to their pleiotropic effects, have been attractive but elusive targets. Indirect targeting approaches include inhibition of upstream kinases such as TAK1 for suppression of NF $\kappa$ B signaling and downstream effectors such as FGF signaling in HOXA-upregulated leukemia. Other strategies include targeting scaffolding proteins like BrD4 in the case of MYC or coactivators such as menin to suppress HOX expression; disrupting critical protein interactions in the case of  $\beta$ -catenin:TCF/LEF, and preventing transcription factor binding to DNA as in the case of PU.1 or FOXM1. We comprehensively describe the mechanism of deregulation of transcription factors in genomic subsets of AML, consequent pathway addictions, and potential therapeutic strategies.

## Introduction

In spite of remarkable progress in the genomic classification and risk stratification of acute myeloid leukemia (AML) by the WHO (1) and ELN (2), 5-year survival rates still stagnate at 30% (SEER data 2009–2015). This is primarily due to the rapid emergence of resistance to standard cytotoxic chemotherapy. The development of effective next-generation therapeutic options against AML depends on mechanistic understanding of AML biology. In the current review, we try to link the genomically and clinically defined ELN leukemia categories with critical transcription factor dependencies. We will highlight several mechanisms of transcription factor deregulation in AML.

Loss-of-function mutations in transcription factors critical for hematopoietic stem and progenitor cell differentiation include RUNX1, and CEBP- $\alpha$  and germline mutations in these transcription factors have also been observed in familial myeloid neoplasms (Fig. 1; ref. 3). In addition, loss of function of tumor suppressor p53 results in high-risk AML frequently associated with complex karyotype and chemotherapy resistance.

Disruption of chromatin-associated protein complexes in the case of *MLL*- and *NUP28*-rearranged leukemia can result in altered histone methylation and consequent overexpression of the HOXA cluster of oncogenic transcription factors.

Intracellular cytoplasmic delocalization can inactivate important transcription factors for granulocytic differentiation such as PU.1 in

the subset of AML characterized by *NPM1* mutations. Concurrent inactivation of the pro-oncogenic transcription factor FOXM1, another important binding partner of nucleophosmin, may play a role in the clinically observed favorable responses to chemotherapy in this subset of AML patients (Fig. 1).

Although molecular aberrations in AML occur in diverse genes and combinations, many of these converge on a finite number transcriptional networks (4). Discovery of the dependencies of the dysregulated transcriptional programs in AML can allow the identification of important therapeutic targets. We will discuss key vulnerabilities in oncogenic and tumor suppressor transcription factors that are dysregulated in AML, including findings from our laboratory.

## Transcription Factor Activity Altered by Recurrent Translocations in AML

Transcription factors can be directly involved in translocations or indirectly influenced by dysregulation of coactivators.

### HOXA

The *HOX* genes encode a family of homeodomain-containing transcription factors exhibiting temporally restricted expression (5) during hematopoietic cell differentiation, and their deregulation is an important step toward malignant transformation. The mixed lineage leukemia (*MLL*) gene encodes a transcriptional activator that regulates HOX expression through interaction with chromatin-associated protein complexes including menin and the histone H3 lysine 79 (H3K79) methyltransferase DOT1L (6). AML patients with chromosomal translocations or partial tandem duplications involving the *MLL* gene have a poor prognosis that has been linked to enhanced and sustained transcription of *HoxA9* and *HoxA10* (7) by *MLL* fusion oncoproteins. There is some controversy around the level of addiction to HOXA in *MLL*-rearranged leukemias. *HoxA9*<sup>-/-</sup>-deficient progenitors transduced with *MLL*-Gas7 (8) are capable of initiating leukemia, and *MLL*-AF9<sup>+/+</sup> knock-in mice with *HoxA9* deletion (9) show no differences in disease development compared with mice with germline *HoxA9*. Other


<sup>1</sup>Department of Medicine, University of Illinois, Chicago, Illinois. <sup>2</sup>Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois. <sup>3</sup>Jesse Brown VA Medical Center, Chicago, Illinois.

**Corresponding Author:** Andrei L. Gartel, University of Illinois at Chicago, 840 S Wood St, Room 1041, Chicago, IL 60612. Phone: 312-996-1855; Fax: 312-413-0342; E-mail: agartel@uic.edu

Mol Cancer Ther 2021;20:229–37

doi: 10.1158/1535-7163.MCT-20-0115

©2020 American Association for Cancer Research.



**Figure 1.**

Mechanisms of transcriptional deregulation in AML. Chromosome translocations resulting in MLL and NUP98 fusion oncoproteins result in increased expression of the oncogenic transcription factor *HOXA*. Core bind factor translocations including *inv(16)* and *t(8;21)* result in fusion proteins that have a dominant-negative effect on the tumor suppressor RUNX1. *MYC* is transcriptionally silenced by wild-type RUNX and CEBP- $\alpha$ , and mutations/loss of function of these genes leads to its overexpression. Nuclear translocation of NF-kappa by loss of its negative regulator I $\kappa$ B is induced by the *FLT3<sup>ITD</sup>* mutation and loss of function of wild-type RUNX1. Haploinsufficiency of the *APC* and *CK1A1* genes in 5q-AML leads to nuclear translocation of beta-catenin. Once nuclear, it binds to TCF; this complex is stabilized by TBL1, and is transcriptionally active. *NPM1* mutations result in cytoplasmic export of PU.1, a critical myeloid differentiation factor. Loss-of-function mutations in *CEBP- $\alpha$* , *p53*, and *RUNX* results in loss of their tumor suppressor function.

studies show an abrogation of leukemia development with *HOXA9* knockdown in *MLL*-AF9 leukemia (10). It is also known that overexpressing *HOXA9* alone does not induce AML in murine bone marrow transplant studies, but requires collaboration with *Meis1* (11) although *HOXA10* alone can cause AML (12).

Another important but rare subset of AML that is highly dependent on *HOXA* transcriptional activity is *NUP98*-rearranged AML (13). Although *NUP98* can be directly fused to *HoxA9*, it has been shown that irrespective of the binding partner, *NUP98* fusion proteins directly interact with nonspecific lethal (NSL)/*MLL1* histone-modifying complexes and colocalize on chromatin where they are associated with *HOX* gene promoter regions. *NUP98*-rearranged leukemias show elevated expression of *HOXA* and *HOXB* cluster genes, and mouse model systems have recapitulated this high-level expression.

In addition, several publications support high expression of multiple members of the *HOXA* and *HOXB* clusters in *NPM1*-mutant AML (14, 15). Using allele-specific gene editing and treatment with nuclear export inhibitors, Brunetti and colleagues (16) demonstrated a dependency of *HOX* expression, and AML cell differentiation and proliferation on the aberrant cytoplasmic localization of nucleophosmin (NPM).

The DOT1L inhibitor EPZ-5676 inhibits methylation of H3K79 resulting in downregulation of *HOXA9*, which correlated with the anticancer activity of this drug in *MLL*-rearranged AML xenografts (17). The much-anticipated phase I clinical trial in *MLL*-rearranged leukemia showed target inhibition and evidence of bone marrow differentiation but modest antileukemic activity (18). A more recent therapeutic approach is disrupting the interaction of menin with *MLL* fusion proteins, which was shown to be a critical cofactor

for MLL-mediated transformation. MI-503 and MI-463 (19) and VTP50469 (20) are inhibitors of the menin-MLL interaction, with preclinical efficacy against *in vivo* models of MLL-rearranged acute leukemia. Two phase I/II clinical trials of menin inhibitors KO-539 (NCT04067336) and SNDX-5613 (NCT04065399), an analogue of VTP50469, are ongoing in cases of AML with MLL rearrangement or the NPM1 mutation.

Chromatin immunoprecipitation-based screening in AML cells identified the gene encoding fibroblast growth factor 2 (*FGF2*) as a HOXA10 target gene. The MLL fusion protein Mll-Ell was shown to activate the *FGF2* promoter in a HOXA9- and HOXA10-dependent manner resulting in the autocrine production of *FGF2* (21). *FGF2*/*FGFR* inhibitors including kinase inhibitors, *FGF* ligand traps and small molecules that inhibit *FGF2* binding to *FGFRs* are being evaluated for the treatment of different types of cancers, including leukemia (22, 23). This class of drugs may inhibit the expansion of myeloid progenitors mediated by HOXA 9 and 10 and a clinical trial (NCT03513484) is underway testing this concept.

### RUNX1

The Runt-related transcription factor 1 (*RUNX1/AML1*) gene located on chromosome 21q22 is the most frequent target for chromosomal translocation in leukemia. In normal hematopoiesis, *RUNX1* recruits its heterodimeric partner CBF $\beta$  to form the core binding factor (CBF) transcriptional complex that regulates differentiation, ribosome biogenesis, cell-cycle regulation, and TGF-beta signaling pathways. *RUNX1* is indispensable for the establishment of definitive hematopoiesis, and heterozygous germline mutations result in a highly penetrant familial platelet disorder with a predisposition to AML (24).

The subset of favorable risk AML is typified by chromosomal rearrangements involving the CBF in AML. A translocation involving chromosomes 8 and 21 or inversion *inv(16)* (p13;q22) are found in 15% and 8% of AML cases, respectively, and both result in inhibition of wild-type *RUNX1* through different mechanisms. In *t(8;21)*, a corepressor, eight-twenty-one (ETO; ref. 25) is fused to the gene encoding the CBF subunit *RUNX1/AML1*. This fusion oncoprotein co-opts wild-type *RUNX1/AML1* function and recruits epigenetic modifiers including histone deacetylases. Similarly, the chimeric protein CBF $\beta$ -SMMHC resulting from inversion 16 binds to and functions as a dominant-negative regulator of wild-type *RUNX1* (26) and associates with HDAC8. In both cases, there is a dependency on histone deacetylation for transcriptional silencing leading to preclinical (27) and clinical studies (28) with the HDAC inhibitors in CBF AML.

In addition to translocations, somatic heterozygous *RUNX1* mutations have been detected in up to 20% of cases of myelodysplastic syndrome and AML with MDS-related changes and are associated with adverse outcome in AML (29). The main mutations in *RUNX1* described in AML are missense mutations found in the RUNT domain responsible for DNA binding and protein heterodimerization, and nonsense or frameshift mutations distributed throughout the entire gene that exert a dominant-negative effect on the transactivation activity. Approximately 30% of *RUNX1* mutations occur in combination or are associated with loss of heterozygosity, both of which lead to a complete loss of wild-type *RUNX1*. Increased *RUNX1* inactivation in hematopoietic cells increases the propensity to develop leukemia, suggesting a dependency on *RUNX1* protein dosage for disease onset (30).

A novel approach to target *RUNX1* was the identification of compounds through a high-throughput screen to allosterically inhibit *RUNX1* interaction with the oncogenic fusion protein CBF $\beta$ -SMMHC. One compound developed from this screen, AI-10-49, was

shown to disrupt CBF $\beta$ -SMMHC binding to *RUNX1* (31) and induced preferential apoptosis of *inv(16)* AML cells (32). This study provided important proof of concept for targeted therapies aimed at dysregulated transcription in specific genomic subsets of AML.

Although *RUNX1* is generally considered to function as a tumor suppressor in the development of leukemia, wild-type *RUNX1* is necessary to sustain leukemia caused by leukemogenic fusion proteins (33). The dependency on wild-type *RUNX1* was therapeutically leveraged in a study (34) where suppression of *RUNX1* was preferentially active against AML blasts expressing mutant *RUNX1*. It was shown that *RUNX2* and *RUNX3* (35) can compensate for *RUNX1* silencing, simultaneous attenuation of all *RUNX* family members was more effective. The alkylating agent-conjugated pyrrole-imidazole polyamides, designed to bind to consensus *RUNX*-binding sequences, were active in a xenograft mouse model of AML (35), and this effect was mediated by p53 stabilization.

These studies on the pro-oncogenic role of *RUNX1*, while challenging the paradigm, are not well reconciled with clinical observation as disease course is not ameliorated in *RUNX1*-mutant AML with loss of heterozygosity at the wild-type allele. This dependency on the wild-type allele may be context dependent and lost in the setting of additional acquired mutations.

### MYC

The ubiquitous proto-oncogene *MYC* transcriptionally regulates cell growth and metabolism. With progressive myeloid differentiation, there is a critical downregulation of *MYC* expression and ectopic expression blocks granulopoiesis. Epigenetic regulation at the *MYC* locus plays a critical role in myeloid differentiation and leukemogenesis. AML proteins are dependent on myc-induced self-renewal and survival (36, 37). The silencing of E2-2 by AML-ETO is an important mechanism for activation of *MYC* relevant to the clinical outcome of *t(8;21)* that can be reversed by overexpression of this transcription factor (38). In *inv(16)* AML, the impressive activity of AI-10-49 in the previous section was attributed primarily to the release of *RUNX1* from CBF $\beta$ -SMMHC complex allowing replacement of chromatin remodeling complexes at three *MYC* distal enhancer elements (32). An additional ELN subset of AML with increased *MYC* expression is *CEBP $\alpha$* -mutated (39) cases based on the negative regulation of *MYC* by *CEBP $\alpha$* .

*MYC* has been directly implicated in myeloid leukemogenesis when ectopically overexpressed in murine bone marrow progenitor cells (40). High levels of *MYC* expression are associated with inferior survival outcomes (41) and contribute to chemoresistance in AML. One mechanism for this activity is the direct transcriptional regulation of the histone methyltransferase *EZH2* (42).

*Myc* is challenging to target directly, given the absence of small-molecule binding pockets. One approach to surmount this hurdle has been targeting the transcription of this gene by destabilizing super-enhancer complexes. This has been accomplished using bromodomain-containing 4 (BRD4) inhibitors, which disrupt BETP binding to acetylated histones (43, 44), as well as proteolysis-targeting chimera (PROTAC) that direct BET proteins toward cereblon-mediated proteasomal degradation (45).

As a short half-life protein *Myc* also lends itself to strategies that inhibit translation. Homoharringtonine (HHT), an inhibitor of protein elongation, targets short-lived proteins such as *Myc*, *Cttnb1*, and *Mcl1* and has preferential activity in *t(8;21)* AML (46). Recent work shows the antileukemic effect of HHT is also linked to the drug binding to NKRFB, a regulator of NF- $\kappa$ B activity, thereby affecting transcription of the *MYC* gene and lowering mRNA levels (47).

Khan et al.

## Transcription Factor Activity Modulated by Cellular Localization

### NF-kappa B

The transcription factor nuclear factor kappa B (NF- $\kappa$ B) comprises five members: Rel (c-Rel), RelA/p65, RelB, p50, and p52. Members of the NF- $\kappa$ B family exist in homo- or heterodimeric states and regulate the activation of specific target genes. In basal conditions, NF- $\kappa$ B proteins are predominantly cytoplasmic, associating with members of the inhibitory I $\kappa$ B family, which inhibit its DNA binding activity. Phosphorylation of I $\kappa$ B results in proteasomal degradation, allowing free NF- $\kappa$ B to enter the nucleus and activate transcription (48).

NF- $\kappa$ B is constitutively activated in AML CD34<sup>+</sup> cells and confers resistance to apoptosis (49). The importance of NF- $\kappa$ B as a target in leukemogenesis was shown by overexpression of mutant super-repressor I $\kappa$ B family members that attenuated AML development (50). Another study showed that activation of noncanonical NF- $\kappa$ B signaling by stabilization of NF- $\kappa$ B-inducing kinase (NIK) resulted in suppression of the canonical pathways and inhibited AML in animal models (51).

Several mechanisms have been identified for NF- $\kappa$ B upregulation in AML. CEBP $\alpha$ , as well as its mutant variants, interact with NF $\kappa$ B p50 and induce a subset of NF $\kappa$ B target genes, including prosurvival Bcl-2 and FLIP, through promoter binding (52). In t(8;21), loss of the c-terminal region of AML1 (RUNX1) prevents binding to, and inhibition of, I $\kappa$ B kinase (IKK), which results in NF- $\kappa$ B activation (53). FL3-ITD-mutated AML cells have enhanced activation of the threonine kinase TAK1 that serves as an important upstream modulator of NF-kappa (54). Also, FLT3 binds directly and activates IKK2, which induces the canonical NF- $\kappa$ B pathway (55). Another mechanism of upregulation in AML cells is Aurora kinase A, which activates I $\kappa$ B kinase complex through TRAF-interacting protein (TIFA), causing degradation of I $\kappa$ B. *In vivo* delivery of TIFA-inhibitory fragments potentiated the cytotoxicity of chemotherapy in murine xenografts (56).

High proteasome activity in AML patients positively regulates NF- $\kappa$ B activity (57) by degradation of ubiquitinated phosphorylated I $\kappa$ B $\alpha$ , and proteasome inhibitors exhibited selective toxicity for leukemic stem cells (58). These observations provided the rationale for the phase I/II clinical trials for the treatment of AML patients with proteasome inhibitor bortezomib in combination with chemotherapy (59) or hypomethylating agent decitabine (60) due to suppression of SPI1/NF- $\kappa$ B-dependent DNA methyltransferase (61).

The anti-inflammatory agent choline-magnesium trisilylate (62) was evaluated in combination with chemotherapy in a phase II randomized clinical trial. Gene-expression analysis of patient samples showed the use of this drug resulted in modulation of a subset of NF- $\kappa$ B target genes that were upregulated in response to chemotherapy (63).

Pevonedistat (MLN4924) inhibits NEDD8-mediated protein degradation by Cullin-RING ubiquitin ligases. This drug has shown promising clinical results in AML (64) and induces stabilization of I $\kappa$ B $\alpha$ , which inhibits nuclear NF-kappa in AML cells. Inhibition of the NF $\kappa$ B target superoxide dismutase 2 (SOD2) and resultant oxidative stress is critical to the activity of this drug (65).

Currently available TAK1 inhibitors 5z-7-oxozeaenol and AZ-TAK1 that block the phosphorylation and thereby the activity of TAK1 inhibited leukemic stem cells in an NF- $\kappa$ B-dependent manner (66). Another therapeutic approach utilizing the noncanonical NF- $\kappa$ B pathway is the use of SMAC mimetics which antagonize the inhibitors of apoptosis (IAP) family (67). By stimulating degradation

of the c-IAP proteins, SMAC mimetics lead to accumulation of NF- $\kappa$ B-inducing kinase (NIK), and induction of NF- $\kappa$ B target genes such as TNF $\alpha$ , which in turn engages an autocrine/paracrine loop to trigger apoptosis.

### Beta-catenin/TCF

In normal hematopoiesis, the Wnt/ $\beta$ -catenin pathway is active in primitive hematopoietic stem cells but downregulated with lineage commitment. In comparison, leukemic stem cells are dependent on canonical Wnt/ $\beta$ -catenin signaling for survival and self-renewal, suggesting that aberrant reactivation of  $\beta$ -catenin signaling is required for transformation. Inhibition of  $\beta$ -catenin phosphorylation status determines its nuclear localization, the unphosphorylated ("activated") form localizes to the nucleus where it binds to the members of the T-cell factor/lymphoid enhancer-binding factor (TCF/LEF) transcription factor family, thereby converting them from transcriptional repressors into activators. Wang and colleagues (68) showed an increased level of unphosphorylated  $\beta$ -catenin in leukemic cells and deletion of  $\beta$ -catenin impaired *MLL*- or *HOXA9*-induced leukemia development in murine models, reinforcing its role as an oncogene in leukemia. The subset of post-MPN secondary AML also has increased beta-catenin stabilization (69), nuclear localization, and *TCF4* transcriptional cofactor activity due to upregulated AKT-mediated GSK3 $\beta$  phosphorylation and inactivation.

Beta-catenin is negatively regulated by the destruction complex comprising adenoma polyposis coli (APC), axin, glycogen synthase kinase  $\beta$  (Gsk3 $\beta$ ), and casein kinase 1 (CK1). The subset of MDS/AML characterized by deletion 5q nearly always have loss of the *APC* gene resulting in hematopoietic stem cell exhaustion (70) mediated largely through a  $\beta$ -catenin-dependent mechanism (71). Conditional deletion of  $\beta$ -catenin rescued abnormal hematopoiesis in an *APC*-deficient murine model. Another important negative regulator of  $\beta$ -catenin located in the common deleted region for del(5q) is casein kinase 1A1 (*CSNK1A1*) (72). These observations fueled attempts to target  $\beta$ -catenin using indomethacin or  $\beta$ -catenin-specific shRNAs resulting in selective inhibition of del(5q) leukemia cells (73). Inhibitors of CK1 also offer therapeutic promise in this AML subset.

There is also a role for cell-extrinsic Wnt signaling in the hematopoietic niche cells (74). Conditional activation of  $\beta$ -catenin signaling within the osteoblast lineage in mice induces overexpression of the Notch ligand *Jagged 1*. The consequent Notch signaling upregulation causes clonal expansion of hematopoietic cells leading to AML.

The interaction between  $\beta$ -catenin and TCF transcription factor is a critical node for Wnt signaling. Peptide inhibitors of this interaction reduced  $\beta$ -catenin-TCF transcriptional activity and decreased the viability of Wnt-dependent cancer cells (75). More recent work shows preclinical therapeutic activity of peptoids, peptidomimetic oligomers that mimic protein secondary structure motifs, to disrupt the  $\beta$ -catenin-TCF interaction (76). A recent approach is the use of small-molecule inhibitor BC2059 to disrupt the binding of the scaffolding protein TBL1 to beta-catenin. TBL1 binds to cytoplasmic  $\beta$ -catenin, protecting it from ubiquitination, and nuclear beta-catenin to facilitate the transcriptional activity of TCF4. Treatment with BC2059, by inducing depletion of nuclear and cytoplasmic  $\beta$ -catenin levels disrupted the transcriptional activity of  $\beta$ -catenin-TCF4. This inhibited growth and survival of leukemia-initiating AML stem-progenitor cells in secondary AML (77). In addition, a proteomic analysis of the  $\beta$ -catenin binding partners in the nuclear and cytoplasmic compartments of leukemia cells (78) revealed the transcriptional partner LEF-1 played an important role in nuclear retention of

$\beta$ -catenin. Small-molecule inhibitors of the  $\beta$ -catenin:TCF/LEF interaction are under development.

### FOXM1

FOXM1 is an oncogenic transcription factor of the Forkhead family with an important role in proliferation and cell-cycle progression. FOXM1 is preferentially expressed in proliferating and malignant cells compared with quiescent or differentiated cells. It is negatively regulated by major tumor suppressors, including RB, p53, and p19. FOXM1 has been implicated in diverse cellular processes encompassing all the hallmarks of cancer, including tumorigenesis, cell proliferation, metastasis.

Recent work (79) showed that FOXM1 is essential for maintaining the quiescence and self-renewal capacity of MLL-AF9 transformed leukemic stem cells *in vivo* by binding to and increasing nuclear  $\beta$ -catenin in this AML model. FOXM1 was found to be overexpressed in FLT3-ITD AML cases (80) and its expression was induced in response to FLT3 ligand treatment of leukemia cells. These are both high-risk AML subsets that could benefit from inhibiting the activity of this transcription factor.

FOXM1 is dependent on its nuclear localization to function as a transcription factor, and its protein interactions have been shown to regulate this localization. It has previously been shown that across multiple tumor types, NPM binds to FOXM1 (81) and their interaction is required for sustaining the level and nuclear localization of FOXM1. The relevance of FOXM1 to AML therapeutic outcomes was recently demonstrated by linking the chemosensitivity conferred by the *NPM1* mutation in AML to the cytoplasmic relocation and consequent inactivation of the oncogenic transcription factor FOXM1 (81, 82). Nuclear FOXM1 was then validated as an independent clinical predictor of chemotherapy resistance in AML (83), and its overexpression in transgenic murine AML models was shown to directly impart chemoresistance. Potentiating chemotherapy by inhibiting FOXM1 could theoretically be applicable all cases with wild-type *NPM1* where FOXM1 would be nuclear.

Peptide inhibitors of FOXM1 have been shown to have antileukemic activity in preclinical models (79, 84). Proteasome inhibitors have been shown to target FOXM1 (85) by stabilizing HSP70, which is a negative regulator of FOXM1 (86). In binding to FOXM1, HSP70 inhibits the DNA binding of FOXM1 and its transcriptional activity. Clinically approved proteasome inhibitors ixazomib and bortezomib inhibit FOXM1 and sensitize AML cells to chemotherapy in preclinical studies (82).

It has previously been shown that the mitotic kinase MELK binds and phosphorylates the oncogenic transcription factor FOXM1 in glioblastoma stem-like cells (GSC; ref. 87). A novel MELK inhibitor OTS167 is being evaluated in the treatment of relapsed leukemia and has been shown to suppress FOXM1 (88). High-throughput screening lead to the identification of FDI-6 (89), a novel small-molecule inhibitor of FOXM1 that blocks DNA binding. It has been shown to bind directly to FOXM1, displacing it from its genomic targets in breast cancer.

### PU.1

The Ets-domain transcription factor PU.1 plays an important role in hematopoietic stem cell maintenance by regulating differentiation, proliferation, and survival (90). It was recognized over a decade ago that PU.1 cooperated with interferon regulatory factors (Irf2 and Irf8) to activate a set of phagocyte-specific genes in neutrophils and monocytes (91). More recently, it was shown that PU.1 cooperates with CEBPA and RUNX1 to direct myeloid differentiation. Although

loss-of-function mutations/translocations of *CEBPA* and *RUNX1* are well recognized in AML, recurrent alterations to PU.1 have not been found. However, interaction with NPM is an important determinant of PU.1 activity, and *NPM1* mutations in AML have been shown to delocalize PU.1 to the cytoplasm (92). By dislocating PU.1 into the cytoplasm, mutant NPM disrupts the PU.1/CEBPA/RUNX1 transcription factor complex, thereby uncoupling proliferation from differentiation. Importantly, this differentiation arrest was reversed by clinical small molecules that inhibit nuclear export such as selinexor or depletion of corepressor DNMT1 from the CEBPA/RUNX1 complex, a finding that opens the door to differentiation therapies for patients with *NPM1*-mutant AML.

Another study indicates the novel function of PU.1 in cell death responses to clinically relevant drugs in AML cells (93). PU.1 significantly prevents NF- $\kappa$ B-mediated upregulation of antiapoptotic genes such as *cFLIP*, *MCL-1*, *BCL-2*, and *BCL-XL* upon TRAIL treatment. Moreover, PU.1 deficiency significantly increased AML cell resistance to anthracycline treatment. These results reveal a new facet of PU.1's tumor suppressor function during antileukemic therapies.

Overexpression of PU.1 is sufficient to trigger differentiation and apoptosis of AML samples (94) but difficult to achieve pharmacologically. Paradoxically, Debre and colleagues suggest that elimination of PU.1 has therapeutic benefit in leukemia (95) based on the observation that complete loss of PU.1 leads to stem cell failure (96). Small molecules of the heterocyclic diamidine family were developed to allosterically interfere with PU.1-chromatin binding through interaction with the DNA minor groove that flanks PU.1-binding motifs. These small molecules disrupted the interaction of PU.1 with target gene promoters causing downregulation of canonical PU.1 transcriptional targets and decreased tumor burden resulting in increased survival of AML xenotransplant models. Additional experiments should reconcile these opposing effects of manipulating PU.1 in AML.

## Transcription Factor Mutations Causing Loss of Function

### p53

The tumor suppressor p53 has a critical role in DNA damage response by inducing cell-cycle arrest to enable repair or consigning unsalvageable cells to apoptosis. *TP53* mutations are present in <10% of *de novo* AML patients (97) but is enriched in therapy-related AML (t-AML) with a prevalence of 30% to 40% (98, 99). Moreover, in four cases of t-AML, the *TP53* mutation predated the development of disease or chemotherapy exposure (100). These data suggest a model in which rare hematopoietic stem and progenitor cells carrying age-related *TP53* mutations are resistant to chemotherapy and expand preferentially after treatment. This observation was reiterated in a murine Fanconi anemia model (*FNCC*<sup>-/-</sup>) where haploinsufficiency of *TP53* in the Fanconi anemia mice (*FNCC*<sup>-/-</sup>/*TP53*<sup>+/-</sup> mice) resulted in the rapid onset of AML in response to inflammatory stress and evidence of accumulation of DNA breaks and radials in the bone marrow (101).

*TP53* mutations in AML have a 2-fold effect of loss of transactivating function of p53 and downregulation of the ubiquitin ligase MDM2 which results in stabilization of mutant protein (102). This results in increased microsatellite instability in multiple loci in 94% of AML patients with *TP53* mutations (99). Recent studies utilized CRISPR-Cas9 to establish a dominant-negative effect influences clonal selection of *TP53* mutations in myeloid leukemias (103).

Khan et al.

In AML cells while the incidence of *TP53* mutations is low, dysregulation of p53 function appears to be a frequent event (104) mediated through overexpression of canonical negative regulators such as MDM2 and/or its homolog MDM4 or p14ARF inactivation. Proteomic studies confirm MDM2 overexpression occurs in over a third of patients with *TP53* wild-type AML resulting in very low levels of p53 protein and an outcome similar to *TP53*-mutant cases.

In an alternate paradigm, a recent study identified a neomorphic function of the *R175H* mutation, a mutant form of *TP53* that represents the most common allele in patients with AML. This mutant p53 exerts its effect by enhancing cellular self-renewal in HSPCs through a novel mediator, FOXH1. Suppression of either mutant p53 or FOXH1 ablated this stemness capacity by triggering differentiation (105).

AMG 232 is an oral, selective MDM2 inhibitor that restores p53 tumor suppression by blocking the MDM2–p53 interaction (106). This drug was well tolerated as monotherapy and in combination with a MEK inhibitor in relapsed/refractory AML (107). It was shown to upregulate p53 transcriptional targets in correlative studies and responses were restricted to *TP53* wild-type AML.

APR-246 is a first-in-class small molecule that covalently binds to the p53 core domain, modifies cysteine residues inducing thermodynamic stabilization, which can restore wild-type activity. The first-in-human study with this compound showed clinical activity in an AML patient with a somatic *TP53* core domain mutation. Preclinical studies in patient AML samples showed APR-246 reactivates the p53 pathway and can induce an apoptosis program and downregulate oncogenic FLT3 signaling (108). Clinical phase II studies of APR-246–based combination therapy demonstrated unprecedented response rates of over 80% in *TP53*-mutant MDS and AML (109, 110). The randomized phase III study of APR-246 and azacitidine versus azacitidine in *TP53*-mutant MDS patients has rapidly completed accrual (NCT03745716) and the drug has been granted breakthrough therapy designation for this indication by the FDA.

### CEBP- $\alpha$

The CCAAT enhancer-binding protein alpha (*CEBP- $\alpha$* ) is a tumor suppressor gene located within 19q13.1 that encodes a transcription

factor involved in granulocytic differentiation. The *CEBP- $\alpha$*  mutation is considered a primary event in leukemogenesis and shows three patterns: single allele mutated, biallelic mutations involving an N-terminal and a C-terminal, and homozygous mutation due to loss of heterozygosity. Mutations in the N-terminus of *CEBP- $\alpha$*  cause frameshift and dominant p30 translation which has less transcriptional activity and acts in a dominant-negative fashion. The mutations in the C-terminus of *CEBP- $\alpha$*  reduce its DNA binding activity (111). *CEBP $\alpha$*  is mutated in 10% to 15% of AML cases and can be functionally suppressed in other AML subsets, such as transcriptional repression by the leukemic fusion protein AML1-ETO, post-translational modifications by the oncogenic kinase FLT3-ITD, and protein degradation by the tribbles homologs, Trib1 and Trib2.

Myeloid leukemia factor 1 (MLF1) was recently identified (112) as a naturally occurring inhibitory protein for the E3 ubiquitin ligase complex, Trib1-COP1, which targets *CEBP- $\alpha$* , for degradation. Transcriptional enhancement of *MLF1* expression and/or increased nuclear compartmentalization of MLF1 represent potential strategies for leukemia therapy.

Identification of small molecules that can restore *CEBP- $\alpha$*  activation is a therapeutic strategy in AML. High-throughput screening led to the identification of ICCB280, a quinazolinone derivative, as an inducer of *CEBP- $\alpha$*  (113). Treatment with this compound induced morphologic and functional evidence of myeloid differentiation in AML cells. ICCB280-induced *CEBP- $\alpha$*  and its downstream targets, such as *CEBP- $\epsilon$*  and G-CSFR, at both the mRNA and protein levels and downregulated MYC, which is negatively regulated by *CEBP- $\alpha$* . *CEBP $\alpha$* -p30 requires interaction with cofactor Wdr5 to inhibit myeloid differentiation. The small-molecule OICR-9429 was able to inhibit this interaction, resulting in selective inhibition and differentiation of p30-expressing human AML cells (114).

## Conclusion

Transcription factors contribute to stem cell maintenance, determination of differentiation, and maturation of HSPCs. Mutations, translocations, or aberrant expression of transcription factors can

**Table 1.** Targeted therapies in AML.

WHO classification	Oncogene activation	Loss of tumor suppressor	Targeted therapies	Mechanism of action
Inv(16) t(8;21)	MYC	RUNX1	AI-10-49	Disrupt CBF $\beta$ -SMMHC binding to RUNX1
	MYC	RUNX1	Homoharringtonine	Interferes with myc protein elongation
	NF-KB		Panabinstat, romidepsin	Degradation of AML-ETO fusion protein and myeloid differentiation
MLL (11q23) and HOXA rearrangement	HOXA		EPZ-5676/pinometostat	DOT1L inhibitor
			VTP50469, MI503, MI463	Inhibits interaction of menin with MLL
			Nintedanib	Inhibits HOXA-mediated FGFR signaling
5q-NPM1 <sup>mut</sup>	$\beta$ -catenin	PU-1	BC2059	Disrupts binding of TBL1 to beta-catenin
	HOXA		Selinexor	Nuclear export inhibitor
			DB2115 or DB2313	Inhibit chromatin binding of PU.1
<i>CEBP<math>\alpha</math></i> <sup>-/-</sup>	MYC	<i>CEBP-<math>\alpha</math></i>	ICCB280	Inducer of wild-type <i>CEBP<math>\alpha</math></i>
			OICR-9429	Inhibits mutant <i>CEBP<math>\alpha</math></i> binding to cofactor Wdr5
P53 <sup>mut</sup> FLT3ITD	NF-KB	p53	APR-246	Binds p53 core domain restoring WT function
			Proteasome inhibitor pevonedistat	Induces stabilization of I $\kappa$ B $\alpha$ , which inhibits NF-K
RUNX1 <sup>mut</sup>	RUNX1		Drug-conjugated pyrrole-imidazole polyamides	Inhibit RUNX binding to DNA and are conjugated to alkylator chlorambucil

cause malignant transformation of hematopoietic cells (Fig. 1). In addition, transcriptional plasticity (115) allows malignant cells to use alternative enhancers to sustain the expression of key survival genes.

Transcription factors have not been traditionally considered “druggable,” as they lack enzymatic activities and the DNA binding pockets and protein–protein interaction domains are generally shallow. There have been advances in direct inhibition of transcription factors with the development of PU.1 and RUNX inhibitors and small molecules that blocks the interaction between beta-catenin and its activator TBL1 (Table 1). Insights into critical dependencies of transcription factors, whether it is activation of downstream kinases such as FGF in *MLL*-rearranged AML or stabilizing protein interactions in the case of menin-*MLL*, uncover new therapeutic possibilities.

By linking the WHO genomic classification of AML to subtype-specific salient transcription factor deregulations, we highlight novel strategies to integrate into the treatment approach of AML patients (Table 1).

### Authors' Disclosures

No disclosures were reported.

### Acknowledgments

I. Khan is the recipient of a Leukemia Research Foundation New Investigator grant. EA Eklund is the recipient of NIH R01 CA195642 and BX004635 (VA Merit Review).

Received February 25, 2020; revised August 13, 2020; accepted October 19, 2020; published first November 6, 2020.

### References

- Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood* 2016;127:2391–405.
- Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood* 2017;129:424–47.
- Churpek JE, Bresnick EH. Transcription factor mutations as a cause of familial myeloid neoplasms. *J Clin Invest* 2019;129:476–88.
- Assi SA, Imperato MR, Coleman DJL, Pickin A, Potluri S, Ptasinska A, et al. Subtype-specific regulatory network rewiring in acute myeloid leukemia. *Nat Genet* 2019;51:151–62.
- Sauvageau G, Lansdorp PM, Eaves CJ, Hogge DE, Dragowska WH, Reid DS, et al. Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells. *Proc Natl Acad Sci* 1994;91:12223–7.
- Milne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, Allis CD, et al. *MLL* targets SET domain methyltransferase activity to hox gene promoters. *Mol Cell* 2002;10:1107–17.
- Dorrance AM, Liu S, Yuan W, Becknell B, Arnoczky KJ, Guimond M, et al. *MLL* partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations. *J Clin Invest* 2006;116:2707–16.
- So CW, Karsunky H, Wong P, Weissman IL, Cleary ML. Leukemic transformation of hematopoietic progenitors by *MLL*-*GAS7* in the absence of *Hoxa7* or *Hoxa9*. *Blood* 2004;103:3192–9.
- Kumar AR, Hudson WA, Chen W, Nishiuchi R, Yao Q, Kersey JH. *Hoxa9* influences the phenotype but not the incidence of *MLL*-*AF9* fusion gene leukemia. *Blood* 2004;103:1823–8.
- Faber J, Krivtsov AV, Stubbs MC, Wright R, Davis TN, van den Heuvel-Eibrink M, et al. *HOXA9* is required for survival in human *MLL*-rearranged acute leukemias. *Blood* 2009;113:2375–85.
- Kroon E, Krosl J, Thorsteinsdottir U, Baban S, Buchberg AM, Sauvageau G. *Hoxa9* transforms primary bone marrow cells through specific collaboration with *Meis1a* but not *Pbx1b*. *EMBO J* 1998;17:3714–25.
- Bei L, Huang W, Wang H, Shah C, Horvath E, Eklund E. *HoxA10* activates *CDX4* transcription and *Cdx4* activates *HOXA10* transcription in myeloid cells. *J Biol Chem* 2011;286:19047–64.
- Xu H, Valerio DG, Eisold ME, Sinha A, Koche RP, Hu W, et al. *NUP98* fusion proteins interact with the *NSL* and *MLL1* complexes to drive leukemogenesis. *Cancer Cell* 2016;30:863–78.
- Spencer DH, Young MA, Lamprecht TL, Helton NM, Fulton R, O'Laughlin M, et al. Epigenomic analysis of the *HOX* gene loci reveals mechanisms that may control canonical expression patterns in AML and normal hematopoietic cells. *Leukemia* 2015;29:1279–89.
- Mullighan CG, Kennedy A, Zhou X, Radtke I, Phillips LA, Shurtleff SA, et al. Pediatric acute myeloid leukemia with *NPM1* mutations is characterized by a gene expression profile with dysregulated *HOX* gene expression distinct from *MLL*-rearranged leukemias. *Leukemia* 2007;21:2000–9.
- Brunetti L, Gundry MC, Sorcini D, Guzman AG, Huang YH, Ramabadran R, et al. Mutant *NPM1* maintains the leukemic state through *HOX* expression. *Cancer Cell* 2018;34:499–512.
- Daigle SR, Olhava EJ, Therkelsen CA, Basavathruni A, Jin L, Boriack-Sjodin PA, et al. Potent inhibition of *DOT1L* as treatment of *MLL*-fusion leukemia. *Blood* 2013;122:1017–25.
- Stein EM, Garcia-Manero G, Rizzieri DA, Tibes R, Berdeja JG, Savona MR, et al. The *DOT1L* inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. *Blood* 2018;131:2661–9.
- Borkin D, He S, Miao H, Kempinska K, Pollock J, Chase J, et al. Pharmacologic inhibition of the menin-*MLL* interaction blocks progression of *MLL* leukemia in vivo. *Cancer Cell* 2015;27:589–602.
- Krivtsov AV, Evans K, Gadrey JY, Eschle BK, Hatton C, Uckelmann HJ, et al. A menin-*MLL* inhibitor induces specific chromatin changes and eradicates disease in models of *MLL*-rearranged leukemia. *Cancer Cell* 2019;36:660–73.
- Shah CA, Bei L, Wang H, Platanias LC, Eklund EA. The leukemia-associated *MLL*-*Ell* oncoprotein induces fibroblast growth factor 2 (Fgf2)-dependent cytokine hypersensitivity in myeloid progenitor cells. *J Biol Chem* 2013;288:32490–505.
- Akl MR, Nagpal P, Ayoub NM, Tai B, Prabhu SA, Capac CM, et al. Molecular and clinical significance of fibroblast growth factor 2 (FGF2/bFGF) in malignancies of solid and hematological cancers for personalized therapies. *Oncotarget* 2016;7:44735–62.
- Wu Q, Bhole A, Qin H, Karp J, Malek S, Cowell JK, et al. *SCLL* targeting *FGFR1* to suppress leukemogenesis in syndromic and de novo AML in murine models. *Oncotarget* 2016;7:49733–42.
- Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, et al. Haploinsufficiency of *CBFA2* causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. *Nat Genet* 1999;23:166–75.
- Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, *AML1*. *PNAS* 1991;88:10431–4.
- Lutterbach B, Hou Y, Durst KL, Hiebert SW. The *inv(16)* encodes an acute myeloid leukemia 1 transcriptional corepressor. *Proc Natl Acad Sci U S A* 1999;96:12822–7.
- Bots M, Verbrugge I, Martin BP, Salmon JM, Ghisi M, Baker A, et al. Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. *Blood* 2014;123:1341–52.
- Odenike OM, Alkan S, Sher D, Godwin JE, Huo D, Brandt SJ, et al. Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. *Clin Cancer Res* 2008;14:7095–101.
- Schnittger S, Dicker F, Kern W, Wendland N, Sundermann J, Alpermann T, et al. *RUNX1* mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. *Blood* 2011;117:2348–57.
- Antony-Debre I, Manchev VT, Balayn N, Bluteau D, Tomowiak C, Legrand C, et al. Level of *RUNX1* activity is critical for leukemic predisposition but not for thrombocytopenia. *Blood* 2015;125:930–40.

31. Illendula A, Pulikkan JA, Zong H, Grembecka J, Xue L, Sen S, et al. Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBF $\beta$ -SMMHC delays leukemia in mice. *Science* 2015;347:779–84.
32. Pulikkan JA, Hegde M, Ahmad HM, Belaghzal H, Illendula A, Yu J, et al. CBF $\beta$ -SMMHC inhibition triggers apoptosis by disrupting MYC chromatin dynamics in acute myeloid leukemia. *Cell* 2018;174:172–86.
33. Goyama S, Schibler J, Cunningham L, Zhang Y, Rao Y, Nishimoto N, et al. Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. *J Clin Invest* 2013;123:3876–88.
34. Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Rajapakshe K, et al. RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1. *Blood* 2019;134:59–73.
35. Morita K, Suzuki K, Maeda S, Matsuo A, Mitsuda Y, Tokushige C, et al. Genetic regulation of the RUNX transcription factor family has antitumor effects. *J Clin Invest* 2017;127:2815–28.
36. Steffen B, Knop M, Bergholz U, Vakhrusheva O, Rode M, Kohler G, et al. AML1/ETO induces self-renewal in hematopoietic progenitor cells via the Groucho-related amino-terminal AES protein. *Blood* 2011;117:4328–37.
37. Weng S, Matsuura S. Restoration of MYC-repressed targets mediates the negative effects of GM-CSF on RUNX1-ETO leukemogenicity. *2017*;31:159–69.
38. Liu N, Song J, Xie Y, Wang X-L, Rong B, Man N, et al. Different roles of E proteins in t(8;21) leukemia: E2-2 compromises the function of AETFC and negatively regulates leukemogenesis. *Proc Natl Acad Sci* 2019;116:890–9.
39. Johansen LM, Iwama A, Lodie TA, Sasaki K, Felsher DW, Golub TR, et al. c-Myc is a critical target for c/EBPalpha in granulopoiesis. *Mol Cell Biol* 2001;21:3789–806.
40. Luo H, Li Q, O'Neal J, Kreisel F, Le Beau MM, Tomasson MH. c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. *Blood* 2005;106:2452–61.
41. Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, et al. MYC protein expression is an important prognostic factor in acute myeloid leukemia. *Leuk Lymphoma* 2019;60:37–48.
42. Salvatori B, Iosue I, Djodji Damas N, Mangiavacchi A, Chiaretti S, Messina M, et al. Critical role of c-Myc in acute myeloid leukemia involving direct regulation of miR-26a and histone methyltransferase EZH2. *Genes Cancer* 2011;2:585–92.
43. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. *Nature* 2011;478:524–8.
44. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. *Cell* 2011;146:904–17.
45. Piya S, Mu H, Bhattacharya S, Lorenzi PL, Davis RE, McQueen T, et al. BETP degradation simultaneously targets acute myelogenous leukemic stem cells and the microenvironment. *J Clin Invest* 2019;129:1878–94.
46. Zhu H-H, Jiang H, Jiang Q, Jia J-S, Qin Y-Z, Huang X-J. Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t(8;21). *Leuk Res* 2016;44:40–4.
47. Chen XJ, Zhang WN, Chen B, Xi WD, Lu Y, Huang JY. Homoharringtonine deregulates MYC transcriptional expression by directly binding NF- $\kappa$ B repressing factor. *2019*;116:2220–5.
48. Bosman MCJ, Schuringa JJ, Vellenga E. Constitutive NF- $\kappa$ B activation in AML: causes and treatment strategies. *Crit Rev Oncol Hematol* 2016;98:35–44.
49. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, et al. Nuclear factor- $\kappa$ B is constitutively activated in primitive human acute myelogenous leukemia cells. *Blood* 2001;98:2301–7.
50. Hsieh M-Y, Van Etten RA. IKK-dependent activation of NF- $\kappa$ B contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1. *Blood* 2014;123:2401–11.
51. Xiu Y, Dong Q, Li Q, Li F, Borchering N, Zhang W, et al. Stabilization of NF- $\kappa$ B-inducing kinase suppresses MLL-AF9-induced acute myeloid leukemia. *Cell Rep* 2018;22:350–8.
52. Paz-Priel I, Ghosal AK, Kowalski J, Friedman AD. C/EBPalpha or C/EBPalpha oncoproteins regulate the intrinsic and extrinsic apoptotic pathways by direct interaction with NF- $\kappa$ B p50 bound to the bcl-2 and FLIP gene promoters. *Leukemia* 2009;23:365–74.
53. Nakagawa M, Shimabe M, Watanabe-Okochi N, Arai S, Yoshimi A, Shinohara A, et al. AML1/RUNX1 functions as a cytoplasmic attenuator of NF- $\kappa$ B signaling in the repression of myeloid tumors. *Blood* 2011;118:6626–37.
54. Shanmugam R, Gade P, Wilson-Weekes A, Sayar H, Suvannasankha A, Goswami C, et al. A noncanonical Flt3ITD/NF- $\kappa$ B signaling pathway represses DAPK1 in acute myeloid leukemia. *Clin Cancer Res* 2012;18:360–9.
55. Grosjean-Raillard J, Adès L, Boehrer S, Tailler M, Fabre C, Braun T, et al. Flt3 receptor inhibition reduces constitutive NF $\kappa$ B activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. *Apoptosis* 2008;13:1148–61.
56. Wei T-YW, Wu P-Y, Wu T-J, Hou H-A, Chou W-C, Teng C-LJ, et al. Aurora A and NF- $\kappa$ B survival pathway drive chemoresistance in acute myeloid leukemia via the TRAF-interacting protein TIFA. *Cancer Res* 2017;77:494–508.
57. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF- $\kappa$ B B1 precursor protein and the activation of NF- $\kappa$ B. *Cell* 1994;78:773–85.
58. Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RM, Szilvassy SJ, et al. Preferential induction of apoptosis for primary human leukemic stem cells. *Proc Natl Acad Sci* 2002;99:16220–5.
59. Attar EC, Johnson JL, Amrein PC, Lozanski G, Wadleigh M, DeAngelo DJ, et al. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. *J Clin Oncol* 2013;31:923–9.
60. Roboz GJ, Mandrekars SJ, Desai P, Laumann K, Walker AR, Wang ES, et al. Randomized trial of 10 days of decitabine  $\pm$  bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). *Blood advances* 2018;2:3608–17.
61. Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, et al. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF- $\kappa$ B-dependent DNA methyltransferase activity in acute myeloid leukemia. *Blood* 2008;111:2364–73.
62. Strair RK, Gharibo M, Schaar D, Rubin A, Harrison J, Aisner J, et al. Nuclear Factor- $\kappa$ B modulation in patients undergoing induction chemotherapy for acute myelogenous leukemia. *Clin Cancer Res* 2008;14:7564–8.
63. Medina D, David K, Lin Y, Schaar D, Patel V, Gharibo M, et al. Choline-magnesium trisalicylate modulates acute myelogenous leukemia gene expression during induction chemotherapy. *Leuk Lymphoma* 2017;58:1227–30.
64. Swords RT, Coutre S, Maris MB, Zeidner JF, Foran JM, Cruz J, et al. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. *Blood* 2018;131:1415–24.
65. Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, et al. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. *Blood* 2010;115:3796–800.
66. Bosman MCJ, Schepers H, Jaques J, Brouwers-Vos AZ, Quax WJ, Schuringa JJ, et al. The TAK1-NF- $\kappa$ B axis as therapeutic target for AML. *Blood* 2014;124:3130–40.
67. Fulda S. Promises and challenges of smac mimetics as cancer therapeutics. *Clin Cancer Res* 2015;21:5030–6.
68. Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, et al. The Wnt/ $\beta$ -catenin pathway is required for the development of leukemia stem cells in AML. *Science* 2010;327:1650–3.
69. Liu YC, Lai WC, Chuang KA, Shen YJ, Hu WS, Ho CH, et al. Blockade of JAK2 activity suppressed accumulation of  $\beta$ -catenin in leukemic cells. *J Cell Biochem* 2010;111:402–11.
70. Qian Z, Chen L, Fernald AA, Williams BO, Le Beau MM. A critical role for Apc in hematopoietic stem and progenitor cell survival. *J Exp Med* 2008;205:2163–75.
71. Li W, Hou Y, Ming M, Yu L, Seba A, Qian Z. Apc regulates the function of hematopoietic stem cells largely through  $\beta$ -catenin-dependent mechanisms. *Blood* 2013;121:4063–72.
72. Schneider Rebekka K, Ademà V, Heckl D, Järås M, Mallo M, Lord Allegra M, et al. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. *Cancer Cell* 2014;26:509–20.
73. Li L, Sheng Y, Li W, Hu C, Mittal N, Tohyama K, et al. beta-catenin is a candidate therapeutic target for myeloid neoplasms with del(5q). *Cancer Res* 2017;77:4116–26.
74. Kode A, Manavalan JS, Mosialou I, Bhagat G, Rathinam CV, Luo N, et al. Leukaemogenesis induced by an activating  $\beta$ -catenin mutation in osteoblasts. *Nature* 2014;506:240–4.
75. Grossmann TN, Yeh JTH, Bowman BR, Chu Q, Moellering RE, Verdine GL. Inhibition of oncogenic Wnt signaling through direct targeting of  $\beta$ -catenin. *Proc Natl Acad Sci U S A* 2012;109:17942–7.
76. Schneider JA, Craven TW, Kasper AC, Yun C, Haugbro M, Briggs EM, et al. Design of peptoid-peptide macrocycles to inhibit the  $\beta$ -catenin TCF interaction in prostate cancer. *Nat Commun* 2018;9:4396.



77. Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, et al. Targeting nuclear  $\beta$ -catenin as therapy for post-myeloproliferative neoplasm secondary AML. *2019*;33:1373–86.
78. Morgan RG, Ridsdale J, Payne M, Heesom KJ, Wilson MC, Davidson A, et al. LEF-1 drives aberrant beta-catenin nuclear localization in myeloid leukemia cells. *Haematologica* 2019;104:1365–77.
79. Sheng Y, Yu C, Liu Y, Hu C, Ma R, Lu X, et al. FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML. *Nat Commun* 2020;11:928.
80. Liu LL, Zhang DH, Mao X, Zhang XH, Zhang B. Over-expression of FoxM1 is associated with adverse prognosis and FLT3-ITD in acute myeloid leukemia. *Biochem Biophys Res Commun* 2014;446:280–5.
81. Bhat UG, Jagadeeswaran R, Halasi M, Gartel AL. Nucleophosmin interacts with FOXM1 and modulates the level and localization of FOXM1 in human cancer cells. *J Biol Chem* 2011;286:41425–33.
82. Khan I, Halasi M, Zia MF, Gann P, Gaitonde S, Mahmud N, et al. Nuclear FOXM1 drives chemoresistance in AML. *Leukemia* 2017;31:251–5.
83. Khan I, Halasi M, Patel A, Schultz R, Kalakota N, Chen YH, et al. FOXM1 contributes to treatment failure in acute myeloid leukemia. *JCI Insight* 2018;3:e121583.
84. Buchner M, Park E, Geng H, Klemm L, Flach J, Passequé E, et al. Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia. *2015*;6:6471.
85. Bhat UG, Halasi M, Gartel AL. FoxM1 is a general target for proteasome inhibitors. *PLoS One* 2009;4:e6593.
86. Halasi M, Varaljai R, Benevolenskaya E, Gartel AL. A novel function of molecular chaperone HSP70: suppression of oncogenic FOXM1 after proteotoxic stress. *J Biol Chem* 2016;291:142–8.
87. Joshi K, Banasavadi-Siddegowda Y, Mo X, Kim SH, Mao P, Kig C, et al. MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. *Stem Cells* 2013;31:1051–63.
88. Alachkar H, Mutonga MB, Metzeler KH, Fulton N, Malnassy G, Herold T, et al. Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia. *Oncotarget* 2014;5:12371–82.
89. Gormally MV, Dexheimer TS, Marsico G, Sanders DA, Lowe C, Matak-Vinković D, et al. Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition. *Nat Commun* 2014;5:5165.
90. Scott E, Simon M, Anastasi J, Singh H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. *Science* 1994;265:1573–7.
91. Huang W, Horvath E, Eklund EA. PU.1, interferon regulatory factor (IRF) 2, and the interferon consensus sequence-binding protein (ICSBP/IRF8) cooperate to activate NF1 transcription in differentiating myeloid cells. *J Biol Chem* 2007;282:6629–43.
92. Gu X, Ebrahim Q, Mahfouz RZ, Hasipek M, Enane F, Radivoyevitch T, et al. Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. *J Clin Invest* 2018;128:4260–79.
93. Haimovici A, Humbert M, Federzoni EA, Shan-Krauer D, Brunner T, Frese S, et al. PU.1 supports TRAIL-induced cell death by inhibiting NF- $\kappa$ B-mediated cell survival and inducing DR5 expression. *Cell Death Differ* 2017;24:866–77.
94. Mueller BU, Pabst T, Fos J, Petkovic V, Fey MF, Asou N, et al. ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression. *Blood* 2006;107:3330–8.
95. Antony-Debré I, Paul A, Leite J, Mitchell K, Kim HM, Carvajal LA, et al. Pharmacological inhibition of the transcription factor PU.1 in leukemia. *J Clin Invest* 2017;127:4297–313.
96. Iwasaki H, Somoza C, Shigematsu H, Duprez EA, Iwasaki-Arai J, Mizuno S, et al. Distinctive and indispensable roles of PU.1 in maintenance of hematopoietic stem cells and their differentiation. *Blood* 2005;106:1590–600.
97. Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N Engl J Med* 2013;368:2059–74.
98. Shih AH, Chung SS, Dolezal EK, Zhang SJ, Abdel-Wahab OI, Park CY, et al. Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia. *Haematologica* 2013;98:908–12.
99. Ben-Yehuda D, Krichevsky S, Caspi O, Rund D, Polliack A, Abeliovich D, et al. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. *Blood* 1996;88:4296–303.
100. Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. *Nature* 2015;518:552–5.
101. Hu L, Huang W, Bei L, Broglie L, Eklund EA. TP53 haploinsufficiency rescues emergency granulopoiesis in *FANCC*<sup>-/-</sup> mice. *J Immunol* 2018;200:2129–39.
102. Kabbat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. *Nature* 1997;387:299–303.
103. Boettcher S, Miller PG, Sharma R, McConkey M, Leventhal M, Krivtsov AV, et al. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. *Science* 2019;365:599–604.
104. Quintas-Cardama A, Hu C, Qutub A, Qiu YH, Zhang X, Post SM, et al. p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status. *Leukemia* 2017;31:1296–305.
105. Loizou E, Banito A, Livshits G, Ho YJ, Koche RP, Sanchez-Rivera FJ, et al. A gain-of-function p53-mutant oncogene promotes cell fate plasticity and myeloid leukemia through the pluripotency factor FOXH1. *2019*;9:962–79.
106. Khurana A, Shafer DA. MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388). *OncoTargets Ther* 2019;12:2903–10.
107. Erba HP, Becker PS. Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia. *2019*;3:1939–49.
108. Maslah N, Salomao N, Drevon L, Verger E, Partouche N, Ly P, et al. Synergistic effects of PRIMA-1(Met) (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia. *Haematologica* 2020;105:1539–51.
109. Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, et al. Phase 2 results of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia (AML). *Blood* 2019;134:676.
110. Cluzeau T, Sebert M, Rahmé R, Cuzzubbo S, Walter-petrich A, Lehmann che J, et al. APR-246 combined with azacitidine (AZA) in TP53 mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): a phase 2 study by the groupe francophone des myélodysplasies (GFM). *Blood* 2019;134:677.
111. Pulikkan JA, Tenen DG, Behre G. C/EBP $\alpha$  deregulation as a paradigm for leukemogenesis. *Leukemia* 2017;31:2279–85.
112. Nakamae I, Kato JY, Yokoyama T, Ito H, Yoneda-Kato N. Myeloid leukemia factor 1 stabilizes tumor suppressor C/EBP $\alpha$  to prevent Trib1-driven acute myeloid leukemia. *Blood Adv* 2017;1:1682–93.
113. Radomska HS, Jernigan F, Nakayama S, Jorge SE, Sun L, Tenen DG, et al. A cell-based high-throughput screening for inducers of myeloid differentiation. *J Biomol Screen* 2015;20:1150–9.
114. Grebien F, Vedadi M, Getlik M, Giambruno R, Grover A, Avellino R, et al. Pharmacological targeting of the Wdr5-MLL interaction in C/EBP $\alpha$  N-terminal leukemia. *Nat Chem Biol* 2015;11:571–8.
115. Bell CC, Fennell KA, Chan Y-C, Rambow F, Yeung MM, Vassiliadis D, et al. Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia. *Nat Commun* 2019;10:2723.

# Molecular Cancer Therapeutics

## Therapeutic Vulnerabilities of Transcription Factors in AML

Irum Khan, Elizabeth E. Eklund and Andrei L. Gartel

*Mol Cancer Ther* 2021;20:229-237. Published OnlineFirst November 6, 2020.

**Updated version** Access the most recent version of this article at:  
doi:[10.1158/1535-7163.MCT-20-0115](https://doi.org/10.1158/1535-7163.MCT-20-0115)

**Cited articles** This article cites 109 articles, 55 of which you can access for free at:  
<http://mct.aacrjournals.org/content/20/2/229.full#ref-list-1>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/20/2/229>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.